Skip to main content
Clinical Trials/NCT02932930
NCT02932930
Completed
Not Applicable

Ultrasound Guided Quadratus Lumborum Block for Postoperative Pain in Abdominoplasty: A Randomized Controlled Study

St Joseph University, Beirut, Lebanon1 site in 1 country40 target enrollmentOctober 2016

Overview

Phase
Not Applicable
Intervention
QLB bloc
Conditions
Pain
Sponsor
St Joseph University, Beirut, Lebanon
Enrollment
40
Locations
1
Primary Endpoint
Cumulative morphine consumption
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

The original concept of a quadratus lumborum block (QLB) indicated for analgesia after abdominal surgery was first described by Blanco in 2007. Also referred to as a posterior transversus abdominis plane (TAP) block, the QLB consists in deposition of local anesthetic on either the posterior or the anterolateral border of the quadratus lumborum muscle. TAP blocks have already been proved effective in urologic, abdominal, and gynecologic procedures by blocking the sensory nerve supply to the anterior abdominal wall thus reducing the amount of postoperative analgesic medication. The main advantages of QLB compared to the TAP block is a wider sensory block area and a longer duration of analgesia. This is due to the extension of local anesthetic agents beyond the TAP plane to the thoracic paravertebral space(4).

Previous reports have shown that QLB is effective in providing pain relief after various abdominal operations. However, there are no published reports on QLB for postoperative pain after abdominoplasty. This prospective, randomized, double-blinded, controlled study aims to evaluate the analgesic efficacy, opioids consumption and quality of recovery of QLB in patients undergoing abdominoplasty. Patients scheduled to have abdominoplasty will be randomized to receive bilateral QLB with either ropivacaine 0.2% or normal saline. Post-operative cumulative analgesic medication consumption, pain severity at rest and on movement, as well as quality of recovery will be evaluated and compared in both groups.

Registry
clinicaltrials.gov
Start Date
October 2016
End Date
August 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
St Joseph University, Beirut, Lebanon
Responsible Party
Principal Investigator
Principal Investigator

samer jabbour

MD

St Joseph University, Beirut, Lebanon

Eligibility Criteria

Inclusion Criteria

  • Standard abdominoplasty procedure
  • Written informed consent
  • Age ≥ 18 years

Exclusion Criteria

  • Patient's refusal
  • Allergies to any study medication
  • Inability to comprehend or participate in scoring scales
  • Deformations that could possibly affect the spread of the local anesthetic in the quadratus lumborum muscle plane
  • Quadratus lumborum muscle plane not seen in ultrasound examination
  • Coagulopathy or on anticoagulants

Arms & Interventions

QLB group

Patients will receive at the beginning of the surgery 0.2 ml/kg of 0.2% ropivacaine bilaterally. Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Ropivacaine, 0.2 ml/kg of 0.2% ropivacaine

Intervention: QLB bloc

QLB group

Patients will receive at the beginning of the surgery 0.2 ml/kg of 0.2% ropivacaine bilaterally. Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Ropivacaine, 0.2 ml/kg of 0.2% ropivacaine

Intervention: 0.2% Ropivacaine

Control group

Patients will receive at the beginning of the surgery 0.2 ml/kg of 0.9% normal saline bilaterally. Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Normal saline, 0.2 ml/kg of 0.9 % normal saline

Intervention: QLB bloc

Control group

Patients will receive at the beginning of the surgery 0.2 ml/kg of 0.9% normal saline bilaterally. Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Normal saline, 0.2 ml/kg of 0.9 % normal saline

Intervention: 0.9% normal saline

Outcomes

Primary Outcomes

Cumulative morphine consumption

Time Frame: up to 48 hour

Cumulative morphine consumption in mg while in the PACU and tramadol dose till 48 hour post operatively.

Secondary Outcomes

  • Time to first tramadol dose(up to 48 hour)
  • Postoperative pain severity(up to 48 hour)
  • Quality of recovery(up to 48 hour)
  • Postoperative dynamic pain severity(up to 48 hour)
  • Nausea or vomiting(up to 48 hour)
  • Sedation level(up to 48 hour)
  • Time to first walk(up to 48 hour)

Study Sites (1)

Loading locations...

Similar Trials